Terumo (OTCMKTS:TRUMY) Shares Pass Above 50 Day Moving Average - What's Next?

Key Points

• Terumo Corp.'s stock price crossed above its **50-day moving average** of $17.78, reaching a high of **$18.34** during trading.
• The company reported **$0.08 earnings per share (EPS)** for the last quarter, which was **below analysts' estimates** of $0.15.
• Terumo has a **market cap of $26 billion** and a **debt-to-equity ratio of 0.12**, indicating a solid financial position relative to its liabilities.

Terumo Corp. (OTCMKTS:TRUMY - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $17.78 and traded as high as $18.34. Terumo shares last traded at $17.56, with a volume of 389,522 shares.

Terumo Trading Up 2.7%

The firm has a market cap of $26.00 billion, a PE ratio of 33.77 and a beta of 0.79. The company has a current ratio of 3.00, a quick ratio of 1.78 and a debt-to-equity ratio of 0.12. The business has a fifty day moving average price of $17.78 and a 200 day moving average price of $18.37.

Terumo (OTCMKTS:TRUMY - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.07). Terumo had a net margin of 11.28% and a return on equity of 8.48%. The business had revenue of $1.79 billion during the quarter, compared to analyst estimates of $1.79 billion.

About Terumo

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.